John G Jiang - Fulcrum Therapeut | 人才画像

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 15 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Safety and Efficacy of Losmapimod in Facioscapulohumeral Muscular Dystrophy (redux4): a Randomised, Double-Blind, Placebo-Controlled Phase 2b Trial

Rabi Tawil,Kathryn R. Wagner,Johanna Hamel,Doris G. Leung,Jeffrey M. Statland,Leo H. Wang,Angela Genge,Sabrina Sacconi,Hanns Lochmueller,David Reyes-Leiva,Jordi Diaz-Manera,Jorge Alonso-Perez,Nuria Muelas,Juan J. Vilchez,Alan Pestronk,Summer Gibson,Namita A. Goyal,Lawrence J. Hayward,Nicholas Johnson,Samantha LoRusso, Miriam Freimer,Perry B. Shieh, S. H. Subramony,Baziel van Engelen,Joost Kools, Olof Dahlqvist Leinhard,Per Widholm, Christopher Morabito, Christopher M. Moxham,Diego Cadavid,Michelle L. Mellion,Adefowope Odueyungbo,William G. Tracewell,Anthony Accorsi,Lucienne Ronco, Robert J. Gould,Jennifer Shoskes,Luis Alejandro Rojas,John G. Jiang

LANCET NEUROLOGYno. 5 (2024): 477-486

引用0浏览0WOS引用

An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Participants with Facioscapulohumeral Muscular Dystrophy Type 1

Joost Kools,Nicol Voermans,John G. Jiang, Olga Mitelman,Michelle L. Mellion, Vivekananda Ramana,Baziel G. M. van Engelen

JOURNAL OF THE NEUROLOGICAL SCIENCES (2024)

引用0浏览0WOS引用

Safety and Tolerability of Losmapimod for the Treatment of FSHD (P3-11.010)

Marie-Helene Jouvin, Vivekananda Ramana,John Jiang

Neurology（2024）

引用0浏览0引用

Design of REACH: Phase 3 Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in FSHD (P6-8.007)

Alrabi Tawil,Jay J. Han,Leo Wang,John Vissing,Jeffrey Statland,Jennifer Shoskes,John Jiang

Neurologyno. 17_supplement_2 (2023)

引用0浏览0引用

Muscle Ultrasound in an Open-Label Study of Losmapimod in Subjects with FSHD1

Joost Kools,Nicol Voermans,Karlien Mul,John Jiang,Jennifer Shoskes,Kelly Marshall,Markus Karlsson

NEUROLOGYno. 17 (2023)

引用0浏览0引用

Results from 96 Weeks Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4

Leo Wang,Jay Han,Jennifer Shoskes,John Jiang,Alrabi Tawil

NEUROMUSCULAR DISORDERSno. 17 (2023)

引用0浏览0引用

Results from 96 Weeks Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4 (S48.008)

Leo Wang,Jay J. Han,Jennifer Shoskes,John Jiang,Alrabi Tawil

Neurologyno. 17_supplement_2 (2023)

引用0浏览0引用

Muscle Ultrasound in an Open-Label Study of Losmapimod in Subjects with FSHD1 (P5-8.011)

Joost Kools,Nicol Voermans,Karlien Mul,John Jiang,Jennifer Shoskes, Kelly Marshall,Markus Karlsson

Neurologyno. 17_supplement_2 (2023)

引用0浏览0引用

P.144b Feasibility of Measuring Functional Performance of FSHD Patients Using Wearable Sensors to Quantify Physical Activity

Joost Kools,Nicol Voermans,Karlien Mul,John Jiang,Jennifer Shoskes,Kelly Marshall,Anil Tarachandani,Joanita Figueredo,Damien Eggenspieler

Neuromuscular Disorders (2022): S107-S107

引用0浏览0引用

Whole Body MRI Quantitative Muscle Analysis to Evaluate Efficacy of Losmapimod in a Phase 2 Placebo-Controlled Study in Subjects with FSHD (redux4) (S23.009)

Michelle Mellion,Rabi Tawil,Jeffrey Statland,Leo Wang,Angela Genge, Sabrina Sacconi, Hanns Lochmüller, David Reyes Leiva,Jordi Díaz‐Manera,Jorge Alonso Perez, Nuria Muelas Gomez,Juan Vilchez Padilla,Alan Pestronk,Summer Gibson,Namita Goyal,Johanna Hamel,Lawrence J. Hayward,Nicholas Johnson,Samantha LoRusso, Miriam Freimer,Perry B. Shieh,S.H. Subramony,Doris Leung,Baziel G.M. van Engelen,Joost Kools,Olof Dahlqvist Leinhard,Per Widholm,John Jiang,Adefowope Odueyungbo,William Tracewell,Luis Alejandro Rojas,Anthony Accorsi,Lucienne Ronco, Diego Cadavid, Christopher M. Moxham, Christopher Morabito,Robert W. Gould

Neurologyno. 18_supplement (2022)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn